Why is Glenmark Pharma falling/rising?

As of 13-Jun, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, with its current price at Rs 1,670.90, reflecting a rise of Rs 39.2 or 2.4%. The stock has shown strong performance today, outperforming its sector by 2.69% and reaching an intraday high of Rs 1,673.75. Over the past week, Glenmark has gained 5.09%, and its one-month return stands at 17.94%. The company has demonstrated consistent positive results, with a significant growth in profit after tax over the last four quarters and a low Debt to EBITDA ratio, indicating strong financial health. Additionally, high institutional holdings at 37.8% suggest confidence from knowledgeable investors, further supporting the stock's upward movement.
In the broader market context, Glenmark's recent performance contrasts sharply with the Sensex, which has declined by 1.30% over the past week. This indicates that while the overall market may be facing challenges, Glenmark has managed to deliver substantial returns, outperforming the benchmark consistently over the last three years. The stock's ability to maintain a fair valuation compared to its peers, alongside a robust return on equity and a favorable PEG ratio, reinforces its attractiveness to investors, contributing to its rising price amidst a generally weaker market environment.